PreveCeutical Medical Inc · CSE:PREV
PreveCeutical Medical — Investor Presentation (April 2018)
28 slides from PreveCeutical Medical's investor presentation, April 2018
Slide 1: Corporate Presentation
CSE: PREV OTCQB: PRVCF FSE: 18H CORPORATE PRESENTATION April, 2018 WWW.PREVECEUTICAL.COM
Slide 2: Disclaimer
DISCLAIMER This presentation and its appendices (together the “Presentation”) have been prepared and delivered by PreveCeutical® Medical Inc. (“PreveCeutical” or the “Company”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H). The Presentation and its contents are strictly confidential and may not be reproduced
Slide 3: Corporate Overview
CORPORATE OVERVIEW PreveCeutical Medical Inc. was incorporated on December 15, 2014 under the Business Corporations Act (British Columbia). PreveCeutical’s corporate office is located in Vancouver, Canada and it’s subsidiary PreveCeutical (Australia) Pty Ltd is located in Brisbane, Australia. PreveC
Slide 4: What We Believe
WHAT WE BELIEVE PreveCeutical Medical Inc., led by an experienced team of senior executives and scientists, believes the medical community is transitioning from a system which is “treating people after they become ill” to one of precise, preventive-based treatments. With this focus, PreveCeutical is
Slide 5: Current Programs
CURRENT PROGRAMS MEETING UNMET CLINICAL NEEDS PreveCeutical has partnered with the University of Queensland in multiple research and development programs. Under the agreements, intellectual property and results arising from these programs will be owned by PreveCeutical. Sol-gel platform for nose-to-
Slide 6: Market Opportunities
MARKET OPPORTUNITIES MEETING CURRENT UNMET NEEDS Sol-gel nose-to-brain delivery platform, for CBDs, to Drug delivery technology market provide clinical relief across a range of indications USD $1,669.40 Bn by 2021. 3 from pain, inflammation, seizures and neurological Global neuropathic pain market d
Slide 7: Current Research Programs
CURRENT RESEARCH PROGRAMS CSE: PREV | OTC: PRVCF | FSE: 18H WWW.PREVECEUTICAL.COM 7
Slide 8: Nature Identical Peptide Therapies
NATURE IDENTICAL™ PEPTIDE THERAPIES PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides, consisting of a library of modified peptide analogues, which will then be tested in disease models. Phase two of three is currently underway to identify scorpion v
Slide 9: Peptide Therapeutics: Pain Relief
PEPTIDE THERAPEUTICS PAIN RELIEF This research and development program seeks to develop non-addictive analgesics (for pain relief) as an alternative to existing opioids, which are associated with addiction and tolerance. The opioid epidemic is now associated with more deaths per year than motor vehi
Slide 10: Sol-Gel Therapeutic Delivery Platform
SOL-GEL THERAPEUTIC DELIVERY PLATFORM Developing the first, sustained-release, nose-to-brain delivery system of cannabinoids (CBDs) § Provide clinical relief across a range of indications from pain, inflammation, seizures and neurological disorders. § Proprietary formulation intended for delivery vi
Slide 11: Dual Gene Therapy
DUAL GENE THERAPY ADDRESSING TYPE 2 DIABETES & OBESITY PreveCeutical is working with three leading Australian research centres to co-develop a curative therapy for type 2 diabetes and obesity. PreveCeutical is targeting their siRNA to the tissues that play the greatest role in type 2 diabetes and ob
Slide 12: The Next Phase Through to Evaluation
THE NEXT PHASE THROUGH TO EVALUATION The multi-disciplinary team have mapped the next phase of the project, which spans 4 years, and encompasses five key objectives. 2017 2018 2019 2020 Objective 1: Engineer a panel of novel, ligand-targeted (i.e. liver, skeletal muscle, fatty tissue and brain) bio-
Slide 13: Diabetes Facts & Figures
DIABETES FACTS & FIGURES Kills one person every six seconds 2015 global expenditure $673 Bn USD 2040 projections $802 Bn USD1 Losses in GDP worldwide from 2011-2030 $1.7 Trillion USD2 Europe1 2015 59.8 million 2040 71.1 million North America and Caribbean1 2015 44.3 million 2040 60.5 million Middle
Slide 14: Concussion Therapy Joint Venture
CONCUSSION THERAPY JOINT VENTURE WITH SPORTS 1 MARKETING Joint Venture established to develop a therapeutic product geared towards athletes who suffer from concussions (mild traumatic brain injury or TBI). PreveCeutical and Sports 1 Marketing are investigating whether there is therapeutic potential
Slide 15: Product
PRODUCT CSE: PREV | OTC: PRVCF | FSE: 18H WWW.PREVECEUTICAL.COM 15
Slide 16: CELLB9 Dietary Supplement
CELLB9® DIETARY SUPPLEMENT NATURAL SOLUTION PreveCeutical currently has one product for sale, the CELLB9® Immune System Booster. CELLB9® is an oral dilute solution infused with select peptides sourced exclusively from Caribbean Blue Scorpion venom. The active potentiated ingredients, in CELLB9®, app
Slide 17: PreveCeutical Team
PREVECEUTICAL TEAM CSE: PREV | OTC: PRVCF | FSE: 18H WWW.PREVECEUTICAL.COM 17
Slide 18: PreveCeutical Team
PREVECEUTICAL TEAM Stephen Van Deventer – Chairman, Chief Executive Officer and President Mr. Van Deventer is an experienced businessman and corporate director. Specializing in international corporate relations and business development over the last twenty-five years, Mr. Van Deventer has focused on
Slide 19: PreveCeutical Team
PREVECEUTICAL TEAM Greg S. Reid-Director Filmmaker and Keynote Speaker Greg S. Reid is a #1 best-selling author, entrepreneur, and the CEO of several successful corporations, who has dedicated his life to helping others achieve the ultimate fulfillment of finding and living a life of purpose. In add
Slide 20: PreveCeutical Team
PREVECEUTICAL TEAM Harry Parekh PhD, BSc HonsI - Chief ResearchOfficer Based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), Dr. Parekh also holds adjunct positions at the National University of Singapore, and Manipal University,India. Dr. Parekh heads the Drug
Slide 21: PreveCeutical Team
PREVECEUTICAL TEAM Susan Blond - Director of Publicity Susan Blond started her career painting with The Whitney Museum studio program, but once she got a job at Andy Warhol’s Interview, life was too exciting to paint. She sold ads there primarily to record companies and the magazine took off. She th
Slide 22: PreveCeutical Team
PREVECEUTICAL TEAM Deanna Kress - Director of Corporate Communications & Investor Relations Ms. Deanna Kress has been involved in public capital since 2003 with a focus on Investor Relations and Corporate Communications. Ms. Kress has wide-ranging experience with a number of exploration and producti
Slide 23: PreveCeutical Team
PREVECEUTICAL TEAM Chris Van Deventer – Business Development Mr. Chris Van Deventer has joined PreveCeutical Medical to pursue a career in Corporate Development. Chris brings several years of work experience in the industrial trades and is currently completing a Business Management Diploma. Nicole G
Slide 24: PreveCeutical Australia Team
PREVECEUTICAL AUSTRALIA TEAM PreveCeutical has established a wholly owned subsidiary in Brisbane, Queensland, Australia to bolster their research and development interests. The Australian team, which will be led by Dr. Maher Khaled the Chief Executive Officer, will work closely with Dr. Harry Parekh
Slide 25: Research Collaborators
RESEARCH COLLABORATORS Dr. Rakesh Veedu is leading the Precision Nucleic Acids Theranostics Group, as a McCusker Research Fellow with the Perron Institute for Neurological and Translational Science, based at the Centre for Comparative Genomics at Murdoch University (Perth, Australia). He is an emerg
Slide 26: Advisory Board
ADVISORY BOARD Nicole Goncalves-Krysinski – Foreign Legal Advisor Nicole Goncalves-Krysinski, Esq., is an attorney and a partner in her own law firm in New York City, New York. She has a J.D. from St. John’s University and B.A. from U.C.L.A. Nicole practices in both state and federal courts handling
Slide 27: Partners
PARTNERS CSE: PREV | OTCQB: PRVCF | FSE: 18H WWW.PREVECEUTICAL.COM 27
Slide 28: Please Contact
PLEASE CONTACT Deanna Kress Director of Corporate Communications & Investor Relations Cell: 1 (778) 999-6063 Office: 1 (604) 416-7777 ext. 6288 deanna@preveceutical.com CSE: PREV | OTCQB: PRVCF | FSE: 18H WWW.PREVECEUTICAL.COM 28
PreveCeutical Medical — Investor Presentation (April 2018) on 6ix